Compare LCTX & FNGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LCTX | FNGR |
|---|---|---|
| Founded | 1990 | 2016 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 255.4M | 11.0M |
| IPO Year | 1996 | 2014 |
| Metric | LCTX | FNGR |
|---|---|---|
| Price | $0.95 | $0.15 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $6.25 | N/A |
| AVG Volume (30 Days) | 1.1M | ★ 52.5M |
| Earning Date | 05-14-2026 | 05-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | $14,556,000.00 | ★ $24,132,261.00 |
| Revenue This Year | $109.40 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 53.24 | N/A |
| 52 Week Low | $0.96 | $0.13 |
| 52 Week High | $2.09 | $2.20 |
| Indicator | LCTX | FNGR |
|---|---|---|
| Relative Strength Index (RSI) | 36.60 | 38.68 |
| Support Level | N/A | N/A |
| Resistance Level | $1.18 | $0.36 |
| Average True Range (ATR) | 0.06 | 0.01 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 6.30 | 5.58 |
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.
FingerMotion Inc is engaged in the provision of mobile payment and recharge services in the Chinese market. The Company organizes its operations across four primary areas: telecommunications products and services, marketplace platform and digital commerce infrastructure solutions, data and analytics platform solutions, and Advanced Technology And Platform Solutions. The company generates majority of revenue from telecommunications products and services segment. This segment includes mobile payment and recharge services, as well as enterprise messaging services such as short message services (SMS) and multimedia messaging services (MMS).